

IN THE ABSTRACT OF THE DISCLOSURE

Please amend the Abstract without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

Please replace the ABSTRACT with the ABSTRACT set forth on a separate sheet herewith.

IN THE CLAIMS

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

1. (Amended) An immunological or immunogenic composition for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused myocarditis, and/or abortion and/or intrauterine infection comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

B²
2. (Amended) An immunological or immunogenic composition for the prevention of PCV-2-caused myocarditis and/or abortion and/or intrauterine infection associated with PCV-2 comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

Sub E³
B³
17. (Amended) The composition of claims 1 or 2, wherein the vector comprises a DNA vector plasmid, a *E. coli*, a baculovirus, a pig herpes viruses, including Aujeszky's disease virus, a porcine adenovirus, or a poxvirus, including a vaccinia virus, an avipox virus, a canarypox virus, or a swinepox virus.

18. (Amended) The composition of claim 17 wherein the vector is a DNA vector.

19. (Amended) The composition of claim 17 wherein the vector is a canarypox virus.

B⁴
21. (Amended) The composition of claims 1 or 2, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector, the at least one immunogen from at least one additional pig pathogen can also be the vector expressing the PCV-2 immunogen.

B⁵
24. (Amended) The composition of claims 1 or 2, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 1 to 13.

B

b6
26. (Amended) The composition of claim 24, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 4, 7, 10 and 13.

27. (Amended) The composition of claim 25, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 4, 7, 10 and 13.

b7
31. (Amended) A method for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused myocarditis, and/or abortion and/or intrauterine infection comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1.

32. (Amended) A method for the prevention of PCV-2-caused myocarditis and/or abortion and/or intrauterine infection comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 2.

Sub.E5
b8
43. (Amended) The method of claims 31 or 32, wherein the composition additionally includes at least one immunogen from at least one additional pig pathogen or a vector expressing such an immunogen.

44. (Amended) The method of claim 43 wherein the composition additionally includes at least one immunogen from at least one additional pig pathogen.

46. (Amended) The method of claim 45, wherein the at least one additional pig pathogen is porcine parvovirus (PPV).

Sub.E6
47. (Amended) The method of claims 31 or 32, wherein the vector comprises a DNA vector plasmid, a *E. coli*, a baculovirus, a pig herpes viruses, including Aujeszky's disease virus, a porcine adenovirus, or a poxvirus, including a vaccinia virus, an avipox virus, a canarypox virus, or a swinepox virus.

48. (Amended) The method of claim 47, wherein the vector is a DNA vector.

49. (Amended) The method of claim 47, wherein the vector is a canarypox virus.

b9
50. (Amended) The method of claim 31, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector, the at least one immunogen from at least one additional pig pathogen, can also be the vector expressing the PCV-2 immunogen.

Sub.E4
Sub.E4
51. (Amended) The method of claim 32, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an

Sub C4
immunogen, wherein the vector, the at least one immunogen from at least one additional pig pathogen, can also be the vector expressing the PCV-2 immunogen.

Sub B4
Sub E8
54. (Amended) The method of claims 31 or 32, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 1 to 13.

55. (Amended) The method of claim 47, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 1 to 13.

56. (Amended) The method of claim 54, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 4, 7, 10 and 13.

57. (Amended) The method of claim 55, wherein the vector contains and expresses an ORF selected from the group consisting of ORFs 4, 7, 10 and 13.

Sub 10
58. (Amended) The method of claim 54, wherein the vector contains and expresses ORF 4 and/or 13.

59. (Amended) The method of claim 55, wherein the vector contains and expresses ORF 4 and/or 13.

Sub 5
60. (Amended) The method of claims 31 or 32, wherein the immunogen is recombinantly produced.

Sub 11
61. (Amended) The method of claims 31 or 32, wherein the pig is a female pig.

64. (Amended) The method of claims 31 or 32, wherein the pig is a male pig.

Please add the following claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Sub C6
82. (New) An immunological or immunogenic composition for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused myocarditis comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

Sub 12
83. (New) An immunological or immunogenic composition for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused abortion comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

84. (New) An immunological or immunogenic composition for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising a

pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

Sub. C6
85. (New) An immunological or immunogenic composition for the prevention of porcine circovirus-2 (PCV-2)-caused myocarditis comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

Sub. C6
86. (New) An immunological or immunogenic composition for the prevention of porcine circovirus-2 (PCV-2)-caused abortion comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector expressing and containing and expressing nucleotide sequence for a PCV-2 immunogen.

87. (New) An immunological or immunogenic composition for the prevention of porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence for a PCV-2 immunogen.

88. (New) A method for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused myocarditis comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1.

89. (New) A method for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused abortion comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1.

90. (New) A method for the prevention and/or treatment of porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1.

B12
91. (New) A method for the prevention of PCV-2-caused myocarditis in a pig comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 2.

92. (New) A method for the prevention of PCV-2-caused abortion in a pig comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 2.

*B12
Cancel*

93. (New) A method for the prevention of PCV-2-caused intrauterine infection in a pig comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 2.

Please cancel claims 3, 7, 9-11, 20, 22, 29, 33, 34, and 37-41 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.